messag report earn morn larg line
investor expect compani reiter august guidanc top-line result
invictu potenti binari event stock major focu
investor spoke management earn releas mention
top-line readout includ mpf hazard ratio blurb safeti new signal
aris updat across pipelin increment posit line prior
guidanc updat estim account result maintain buy pt
ripretinib obtain track design investor await top-line invictu result
august readout repres potenti binari event stock
believ stock favor risk-reward balanc see kit inhibitor deep dive given
trial enrol data releas timelin expect event accrual think
invictu could read month mpf result base analysi see follow-
analysi invictu parallel management remain confid ripretinib clinic
profil highlight efficaci gist also potenti improv
toxic rel avapritinib see management meet takeaway note
follow invictu readout updat phase ripretinib result set
stage phase intrigu gist recal phase intrigu
patient trial compar ripretinib sunitinib gist trial continu
enrol current activ recruit site accord clinicaltri gov phase
result previous report esmo link gist includ orr one
respons occur data cutoff would result orr promis
immatur month mpf readout patient censor updat
result later year includ matur mpf data
earli pipelin develop progress on-track compani re-iter prior
guidanc clinic mileston inhibitor rebastinib combin paclitaxel
finish enrol part phase trial patient read
line prior guidanc carboplatin combin cohort read
addit phase dose escal data inhibitor basket
solid tumor read line prior guidanc product continu enrol
patient tenosynovi giant cell tumor tgct expans cohort final ulk
kinas inhibitor see prior note continu preclin studi
track potenti ind
updat estim account result maintain buy pt
end quarter cash equival suffici runway oper
accord compani estim updat estim
account result includ new tier royalti percentag china sale per
agreement zlab see china partnership note maintain buy pt
page analyst certif import disclosur
valuat risk
valuat per share base probability-adjust estim gist
net cash balanc sheet year use discount cash flow analysi
use wacc termin growth rate appli termin year post-assum
gener entri
risk rate valuat includ regulatori commerci setback
potenti emerg new competitor lower product sale expect cash flow-
neg compani may also engag financ activ dilut exist
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
